HealthyNCT04706481
Archival of Human Biological Samples in CU-Med Biobank
An observational study of Healthy and Cancer, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Healthy, Cancer, Heart Diseases
- What is being tested?
- Specimen Collection
- Type of treatment
- Surgery or procedure
- How many people
- 10,000 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Jan 2020to 1 Dec 2050
- How long will I take part?
- 99 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: The diverse group of biorepositories with focus on normal cohorts and cancer-related or other disease cohorts.
Who may be able to join
- Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.
Who cannot join
- Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
CU-Med Biobank
Hong Kong
Terry Or, PhD, 852-26285221, terryor@cuhk.edu.hk
Marcus Law, Master, 852-26285221, marcuslaw@cuhk.edu.hk
About this study
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.
Read the detailed description
CU-Med Biobank will collect and store high-quality specimens from cancer-related or other diseases. All samples are linked to annotated clinical data from approved consented protocols. This system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. This standardized CU-Med Biobank is a pivotal bridge to improve the translation of basic research into clinical applications. These findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.
- Conditions
- Healthy, Cancer, Heart Diseases, Neurological Diseases or Conditions, Kidney Diseases, Diabetes
- Being tested
- Specimen Collection
- Keywords
- Biobanking
- Medical subject headings
- Neoplasms, Heart Diseases, Kidney Diseases, Diabetes Mellitus, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Specimen CollectionProcedure or surgery
Specimens obtained from surgical, phlebotomy or other non-invasive procedure
| Study group | Role | What they receive |
|---|---|---|
| Healthy Control | Healthy subjects who have provided consent for specimen collection Receives: Procedure: Specimen Collection | |
| Cancer or Other Diseases | Diseased subjects who have provided consent for specimen collection Receives: Procedure: Specimen Collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
To distribute human biospecimens for clinical research
By using the biological samples from CU-Med Biobank, translational studies can be done.
Measured: 99 years
To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes
The relationship between different genome/proteome/bacteriome/virome and various diseases can be revealed, thus leading to a better prognostic and diagnostic outcome.
Measured: 99 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2021
- Study start1 Jan 2020
- Primary completion1 Dec 2050 (estimated)
- Study completion1 Dec 2050 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 99 Years
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Professor Ronald C.W. Ma, Chinese University of Hong Kong
- Investigators
- Ching Wan MA, MB BChir, Study chair, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04706481
- Sponsor's protocol ID
- CREC 2019.152
- Status last verified
- Mar 2026
- First submitted
- 28 Dec 2020
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Archival of Human Biological Samples in CU-Med Biobank
- ClinicalTrials.gov ID
- NCT04706481
- Acronym / sponsor ID
- CREC 2019.152
- Conditions
- Healthy, Cancer, Heart Diseases, Neurological Diseases or Conditions, Kidney Diseases, Diabetes
- Keywords
- Biobanking
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Dec 2050 (estimated)
- Study completion
- 1 Dec 2050 (estimated)
- First posted
- 12 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.
Detailed description
CU-Med Biobank will collect and store high-quality specimens from cancer-related or other diseases. All samples are linked to annotated clinical data from approved consented protocols. This system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. This standardized CU-Med Biobank is a pivotal bridge to improve the translation of basic research into clinical applications. These findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 99 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy Control | – | Procedure: Specimen CollectionHealthy subjects who have provided consent for specimen collection |
| Cancer or Other Diseases | – | Procedure: Specimen CollectionDiseased subjects who have provided consent for specimen collection |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The diverse group of biorepositories with focus on normal cohorts and cancer-related or other disease cohorts.
Key inclusion criteria (1 listed)
- Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.
Key exclusion criteria (1 listed)
- Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Specimen CollectionSpecimens obtained from surgical, phlebotomy or other non-invasive procedure | Procedure or surgery | Cancer or Other Diseases, Healthy Control |
Primary outcome
To distribute human biospecimens for clinical research
Time frame: 99 years
By using the biological samples from CU-Med Biobank, translational studies can be done.
To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes
Time frame: 99 years
The relationship between different genome/proteome/bacteriome/virome and various diseases can be revealed, thus leading to a better prognostic and diagnostic outcome.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Webpage of CU-Med BiobankLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
RecruitingPhase 3
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
Pneumococcal Disease
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingPhase 1
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ching Wan MA, MB BChir study chair
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy and Cancer, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Terry OR, Ph.D (852-26285221, terryor@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To distribute human biospecimens for clinical research (time frame: 99 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.